Skip to content
Logo for Thinking About Ob/Gyn

February 9, 2022OB/Gyn

Episode 3.3 When should we use new treatments? Jada and cfDNA

In this episode we discuss the new Jada postpartum hemorrhage device. More importantly, we discuss the process for choosing to utilize new interventions in clinical practice. Then we discuss a recent New York Times article detailing the problem of false positives in the noninvasive prenatal screening tests. 

Links Discussed:

For A New Device To Treat Maternal Bleeding, A Young Entrepreneur’s Big Step Was Passing The Torch

Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage

Merck Buys Alydia

When Evidence Says No, But Doctors Say Yes

Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products

Search Open Payments

Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation

I Investigated the Prenatal Testing Industry

When They Warn of Rare Disorders, These Prenatal Tests Are Usually Wrong

Recent Posts

  • Episode 4.13 OB Emergencies Part 1
  • Episode 4.12 Angle of Progression, Two Layer Closure, and Deliverance
  • Episode 4.11 Amnioinfusions, Stat Cesareans, Braxton-Hicks, and TikTok
  • Episode 4.10 Iron in pregnancy, Sexism in OB/GYN, and the Postpartum visit
  • Episode 4.9 Value Based Care Part 2: Vaginal Delivery (and some other stuff)

Copyright © 2023 Thinking About Ob/Gyn. All Rights Reserved. Theme by ILoveWP.com